A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway.
about
Multiple cues on the physiochemical, mesenchymal, and intracellular trafficking interactions with nanocarriers to maximize tumor target efficiencyRecent Developments in Peptide-Based Nucleic Acid DeliveryComposite nanoparticles for gene delivery.Ligand-targeted theranostic nanomedicines against cancerDelivery of intracellular-acting biologics in pro-apoptotic therapies.Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment.Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics.Emerging links between surface nanotechnology and endocytosis: impact on nonviral gene delivery.Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis.Boron lipid-based liposomal boron delivery system for neutron capture therapy: recent development and future perspective.Delivery of RNAi therapeutics: work in progress.Nanopreparations for organelle-specific delivery in cancerDelivering the promise of small ncRNA therapeutics.Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.SPANosomes as delivery vehicles for small interfering RNA (siRNA).A preorganized β-amino acid bearing a guanidinium side chain and its use in cell-penetrating peptides.Development of a Cell-penetrating Peptide that Exhibits Responsive Changes in its Secondary Structure in the Cellular Environment.A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1/21-47 domain of hepatitis B virus.Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis.Transcytosis-Targeting Peptide: A Conductor of Liposomal Nanoparticles through the Endothelial Cell Barrier.Doxorubicin delivered to MCF-7 cancer cells by superparamagnetic iron oxide nanoparticles: effects on subcellular distribution and cytotoxicity
P2860
Q26827999-D3C1B01F-AAAA-492A-A1F7-A062B12B4E1DQ27487857-5E539F99-04E8-41C0-B9B7-4589EBACFDE8Q30374988-A8E427C3-E84F-4A90-9A4A-14D10CD9617FQ35895637-4CD2F38F-C25E-4165-8C59-D7690E2B85D7Q36588920-38E086C4-202B-4B14-A8A1-A34E1861B3ADQ37363141-284C6596-4AA1-4D9A-A4AB-1F50E3B52ECDQ37572760-BBDAB053-FCD8-4B27-AD12-315DDF90C834Q37850686-1F1E4E37-A7E2-4DD3-8249-3BEDA37E1AADQ38099153-D6A3710E-D54B-4D37-8FF4-61D0C98D1ACEQ38101626-C09DAC84-AF36-4833-8C5E-95071812D212Q38160246-812C2F02-1617-453A-B4C4-440FF66EFC05Q38165639-70097184-9DE5-4DEE-8AB2-1999AC709468Q38226666-EB44B12A-7849-4358-A1F9-9ED83F2ACCD3Q38262399-00B1E534-D63E-400C-AF57-19531FF262F5Q39431804-3E90EB21-5613-4877-8E6A-3FC1E57EB0A9Q41034490-AB50823E-F118-447C-9846-4F5119579546Q41050184-72B97249-B89C-4134-87FD-B69CFE1B17E6Q41758629-831A4B50-FA0B-493D-AA26-3E092D8AD651Q45870768-E72182B7-A3DF-40E3-8DA8-1C3D26DE9219Q51700936-8FD91BAB-9A30-4A54-BD02-22A428CDF18BQ57922140-3506B5D9-BDB6-4688-8300-BFA6CBD01344
P2860
A novel IRQ ligand-modified nano-carrier targeted to a unique pathway of caveolar endocytic pathway.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@ast
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@en
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@nl
type
label
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@ast
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@en
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@nl
prefLabel
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@ast
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@en
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@nl
P2093
P1476
A novel IRQ ligand-modified na ...... of caveolar endocytic pathway.
@en
P2093
Diky Mudhakir
Hidetaka Akita
Hideyoshi Harashima
P304
P356
10.1016/J.JCONREL.2007.10.020
P407
P577
2007-11-04T00:00:00Z